Name (Synonyms) | Correlation | |
---|---|---|
drug1253 | Intravenous saline injection (Placebo) Wiki | 1.00 |
drug658 | Convalescent plasma Wiki | 0.25 |
Name (Synonyms) | Correlation | |
---|---|---|
D003289 | Convalescence NIH | 0.45 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.05 |
D018352 | Coronavirus Infections NIH | 0.04 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
This clinical trial is set out to evaluate the safety and efficacy of allogeneic human dental pulp mesenchymal stem cells in the treatment of severe pneumonia caused by COVID-19; to explore the effects of human dental pulp mesenchymal stem cells in the treatment of severe pneumonia of COVID-19 in terms of reducing mortality and improving clinical prognosis; and to discover a new therapeutic strategy for COVID-19 using allogeneic human dental pulp mesenchymal stem cells.
Description: Time to Clinical Improvement
Measure: TTCI Time: 1-28 daysDescription: Lung Lesion by CT
Measure: Lung lesion Time: 1-28 daysDescription: Th1 cytokines: IL-1β, IL- 2, TNF-a, ITN-γ; Th2 cytokines: IL- 4, IL- 6, IL- 10; Immunoglobulins: IgA, IgG, IgM, and total IgE; Lymphocyte counts: CD3+, CD4+, CD8+, CD16+,CD19+, CD56+.
Measure: Immune function Time: 1-28 daysDescription: Time of SARS-CoV-2 test turns negative
Measure: Time of SARS-CoV-2 clearance Time: 1-28 daysDescription: Blood cell count and classification
Measure: Blood test Time: 1-28 daysDescription: Pulse oximetry
Measure: SPO2 Time: 1-28 daysDescription: Respiratory rate
Measure: RR Time: 1-28 daysDescription: Body temperature
Measure: Body temperature Time: 1-28 daysDescription: Number of the included patients with hDPSCs-related adverse events, e.g. liver or kidney function failure
Measure: Side effects in the treatment group Time: 1-28 daysDescription: C-reactive protein in microgram per litre
Measure: C-reactive protein (mg/L) Time: 1-28 days